Efficacy of Siponimod in secondary progressive multiple sclerosis patients with active disease: the EXPAND study subgroup analysis

被引：0

作者：

Gold, R. ^{[1
]}

Kappos, L. ^{[2
,3
,4
,5
,6
]}

Bar-Or, A. ^{[7
]}

Vermersch, P. ^{[8
]}

Giovannoni, G. ^{[9
]}

Fox, R. ^{[10
]}

Rouyrre, N. ^{[11
]}

Karlsson, G. ^{[11
]}

Cree, B. A. C. ^{[12
]}

机构：

[1] Ruhr Univ Bochum, St Josef Hosp, Dept Neurol, Bochum, Germany

[2] Univ Hosp, Neurol Clin & Policlin, Dept Med, Basel, Switzerland

[3] Univ Hosp, Neurol Clin & Policlin, Dept Clin Res, Basel, Switzerland

[4] Univ Hosp, Neurol Clin & Policlin, Dept Biomed, Basel, Switzerland

[5] Univ Hosp, Neurol Clin & Policlin, Dept Biomed Engn, Basel, Switzerland

[6] Univ Basel, Basel, Switzerland

[7] McGill Univ, Montreal Neurol Inst & Hosp, Neuroimmunol Unit, Montreal, PQ, Canada

[8] Univ Lille, Dept Neurol, Lille, France

[9] Queen Mary Univ London, Barts & London Sch Med & Dent, Blizard Inst, London, England

[10] Cleveland Clin, Neurol Inst, Mellen Ctr Treatment & Res Multiple Sclerosis, Cleveland, OH 44106 USA

[11] Novartis Pharma AG, Basel, Switzerland

[12] Univ Calif San Francisco, Dept Neurol, UCSF Weill Inst Neurosci, San Francisco, CA USA

来源：

MULTIPLE SCLEROSIS JOURNAL | 2019年 / 25卷

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

P750

引用

页码：380 / 381

页数：2

共 50 条

[21] Safety and Tolerability of Siponimod in Patients with Secondary Progressive Multiple Sclerosis
Fox, Robert
Kappos, Ludwig
Bar-Or, Amit
Cree, Bruce
Giovannoni, Gavin
Gold, Ralf
Vermersch, Patrick
Pohlmann, Harold
Wolf, Christian
Dahlke, Frank
Wallstrom, Erik
Sidorenko, Tatiana
[J]. NEUROLOGY, 2017, 88
[22] Siponimod to treat secondary progressive multiple sclerosis
Gajofatto, A.
Turatti, M.
[J]. DRUGS OF TODAY, 2020, 56 (01) : 37 - 46
[23] Siponimod for the treatment of secondary progressive multiple sclerosis
Dumitrescu, Laura
Constantinescu, Cris S.
Tanasescu, Radu
[J]. EXPERT OPINION ON PHARMACOTHERAPY, 2019, 20 (02) : 143 - 150
[24] Siponimod: A Review in Secondary Progressive Multiple Sclerosis
Lesley J. Scott
[J]. CNS Drugs, 2020, 34 : 1191 - 1200
[25] Prospects of siponimod in secondary progressive multiple sclerosis
McGinley, Marisa
Fox, Robert J.
[J]. THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2018, 11
[26] Long-term efficacy and safety of siponimod in patients with secondary progressive multiple sclerosis: Analysis of EXPAND core and extension data up to >5 years
Cree, Bruce A. C.
Arnold, Douglas L.
Fox, Robert J.
Gold, Ralf
Vermersch, Patrick
Benedict, Ralph H. B.
Bar-Or, Amit
Piani-Meier, Daniela
Rouyrre, Nicolas
Ritter, Shannon
Kilaru, Ajay
Karlsson, Goeril
Giovannoni, Gavin
Kappos, Ludwig
[J]. MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (10) : 1591 - 1605
[27] Magnetization Transfer Imaging in Secondary Progressive Multiple Sclerosis Patients Treated with Siponimod: Results from the Phase 3 EXPAND Study
Arnold, Douglas L.
Cree, Bruce A. C.
Bar-Or, Amit
Giovannoni, Gavin
Gold, Ralf
Vermersch, Patrick
Meier, Daniela Piani
Arnould, Sophie
Ritter, Shannon
Karlsson, Goeril
Kappos, Ludwig
Fox, Robert
[J]. NEUROLOGY, 2020, 94 (15)
[28] Siponimod: A Review in Secondary Progressive Multiple Sclerosis
Scott, Lesley J.
[J]. CNS DRUGS, 2020, 34 (11) : 1191 - 1200
[29] Real World Experience with Siponimod in Secondary Progressive Multiple Sclerosis Patients
Gomez-Estevez, I.
Garcia Vasco, L.
Alba Suarez, E.
Quezada Sanchez, J.
Oreja-Guevara, C.
[J]. MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 97 - 97
[30] Efficacy and safety of siponimod in secondary progressive multiple sclerosis - Results of the placebo controlled, double-blind, Phase III EXPAND study.
Kappos, L.
Bar-Or, A.
Cree, B.
Fox, R.
Giovannoni, G.
Gold, R.
Vermersch, P.
Arnould, S.
Sidorenko, T.
Wolf, C.
Wallstroem, E.
Dahlke, F.
[J]. MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 828 - 829

← 1 2 3 4 5 →